A Multi-Institutional Estimation of Interobserver Variability in Glioblastoma Treatment Planning in the EORTC-1709-BTG / CCTG CE.8 trial
Volume: 105, Issue: 1, Pages: E619 - E619
Published: Sep 1, 2019
Abstract
For 14 years (EORTC / NCIC 26981-22981) the standard of care for glioblastoma (GBM) is maximal resection, RT + temozolomide (TMZ) followed by adjuvant TMZ. RT for GBM is conformal/modulated, volume-based with rigorous delineation guidelines for target and organs at risk (OARs) based on imaging (CT-MR). It is expected that the interobserver variability in delineation/planning would be limited. The EORTC 1709-BTG/CCTG CE.8 trial is a...
Paper Details
Title
A Multi-Institutional Estimation of Interobserver Variability in Glioblastoma Treatment Planning in the EORTC-1709-BTG / CCTG CE.8 trial
Published Date
Sep 1, 2019
Volume
105
Issue
1
Pages
E619 - E619
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History